Skip to main content

Table 5 Comparison of Perceived Efficacy of Extended-Release Naltrexone among SAMHSA-Waivered Physicians to Non-Waivered Physicians. Detailed Table Summary: Waivered providers, as compared to non-waivered ones, were more concerned about the following with respect to extended-release naltrexone to treat OUD: diversion (paired t (31.240) = 3.243, p = 0.003), insufficient training (paired t [40]=4.076, p = 0.000), insufficient time (paired t [38]=5.476, p = 0.000), insufficient staff support (paired t [38]=3.762, p = 0.000), insufficient experience (paired t [37]=5.175, p = 0.000), insufficient resources for patient psychosocial support (paired t [41]=5.855, p = 0.000), and insufficient resources for patient withdrawal management (paired t [41]=5.375, p = 0.000).

From: A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder

Perceptions SAMHSA- waivered Physicians Non-waivered Physicians t df Mean Difference Cohen’s d 95% Confidence Interval p
n Mean (SD) n Mean (SD) Lower Upper
Concerns about diversion^ 23 1.83 (0.937) 31 1.129 (0.499) 3.243 31.240 0.697 0.934 0.259 1.135 0.003*
Lack of patient interest 21 2.429 (1.248) 32 2.375 (1.008) 0.172 51 0.054 0.048 −0.571 0.678 0.864
Law enforcement oversight^ 19 1.790 (0.918) 31 1.226 (0.617) 2.369 28.063 0.564 0.721 0.076 1.051 0.025
Professional licensing board oversight^ 18 2.111 (1.231) 31 1.161 (0.523) 3.114 20.614 0.950 1.004 0.315 1.585 0.005
Extended-release naltrexone patients would unfavorably affect my patient mix^ 19 1.895 (1.100) 31 1.194 (0.654) 2.518 25.916 0.701 0.775 0.129 1.274 0.018
My co-workers do not support provision of extended-release naltrexone in my practice^ 16 1.688 (0.946) 31 1.161 (0.523) 2.067 19.846 0.526 0.689 −0.005 1.057 0.052
Managers/administrators do not support provision of extended-release naltrexone in my practice^ 18 2.167 (1.249) 30 1.333 (0.884) 2.483 27.318 0.833 0.771 0.145 1.522 0.019
Reimbursement rates for extended-release naltrexone 16 2.750 (1.125) 29 2.448 (1.298) 0.781 43 0.302 0.249 −0.477 1.081 0.439
Insurance prior authorization requirements^ 18 2.944 (0.938) 32 2.750 (1.191) 0.637 42.622 0.194 0.181 −0.421 0.810 0.528
Insufficient training 21 2.762 (1.179) 31 1.548 (0.961) 4.076 50 1.214 1.129 0.616 1.812 0.000*
Insufficient time 22 2.818 (1.097) 31 1.419 (0.765) 5.476 51 1.399 1.479 0.886 1.912 0.000*
Insufficient staff support 22 2.773 (1.110) 31 1.645 (1.050) 3.762 51 1.128 1.044 0.526 1.729 0.000*
Insufficient experience 24 3.042 (1.160) 30 1.567 (0.935) 5.175 52 1.475 1.400 0.903 2.047 0.000*
Insufficient resources for patient psychosocial support within the community or in my practice 24 3.042 (0.955) 31 1.548 (0.925) 5.855 53 1.493 1.589 0.982 2.005 0.000*
Insufficient resources for patient detoxification within the community or in my practice 24 3.250 (0.989) 31 1.742 (1.064) 5.375 53 1.508 1.468 0.945 2.071 0.000*
  1. Notes: Questions about the perceptions of DEA-waivered physicians with non-waivered physicians were compared in these results using independent samples t-test (α = .05, two-tailed level). * indicates significance once a Bonferroni Correction of α = .05/15 = .0033 was applied. ^ indicates that equal variances are not assumed